newswire, breaking biotechnology and pharma news

Wednesday, February 19, 2014

Biotech/Pharma Companies Targeting Pancreatic Cancer: (SBFM), (NLNK), (LLY), (CELG)

Point Roberts WA, New York, NY - February 19, 2014 ( Biotech Newswire) global news source covering leading sectors including biotech and pharma reports on companies in the sector targeting pancreatic cancer. Stocks mentioned include NewLink Genetics (NLNK), Sunshine Biopharma Inc. ( OTCBB: SBFM ), Eli Lilly and Company (NYSE:LLY) and Celgene (NASDAQ:CELG).

Decision Resources ( ),one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the pancreatic cancer therapy market will nearly double to $1.3 billion in 2022, owing to the launch and rapid uptake of three high-priced agents-Celgene (NASDAQ:CELG)/Taiho's Abraxane, Onconova Therapeutics/Baxter International/SymBio Pharmaceuticals' Estybon and Merrimack Pharmaceuticals' MM-398 (a novel formulation of irinotecan). Even though these agents do not substantially improve the overall survival of pancreatic cancer patients, they will have a significant impact on current treatment.
The Pharmacor Pancreatic Cancer report also finds that significant commercial reward awaits developers of therapies that are more effective and better tolerated than the FOLFIRINOX regimen in this disease, as the need for efficacious, well-tolerated therapies will remain through 2022.
NewLink Genetics (NASDAQ:NLNK) has been of the top gainers for 2014,gaining over 90%.NewLink's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a wide range of oncology indications.
Their product, RAlgenpantucel-L is an investigational HyperAcute™ immunotherapy for pancreatic cancer. The product consists of 2 pancreatic cancer cell lines (HAPa-1 and HAPa-2) that have been genetically modified to express alpha-gal carbohydrates on cell surface molecules.1 Upon injection into the patient, the alpha-gal stimulates an immune response against pancreatic cancer-specific antigens in the tumor cell lines. The patient’s immune system then targets its own pancreatic cancer cells, destroying them.1 In the adjuvant setting, the immune response targets and eradicates residual tumor cells in conjunction with chemotherapy and chemoradiation.1,2.
Algenpantucel-L is currently being studied in combination with standard of care in two phase 3 trials:
Last fall the company reported greater than expected responses to follow-on chemotherapy after treatment with algenpantucel-L or tergenpumatucel-L HyperAcute immunotherapy. Three pancreatic cancer patients were followed for response to subsequent salvage chemotherapy treatment after progressing on algenpantucel-L therapy. All three patients experienced durable (12-36 months), complete responses. Newswire Sunshine Biopharma Inc. ( OTCBB:SBFM ), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, recently announced that it is targeting pancreatic cancer as second indication for its leading compound, Adva-27a.
As previously announced, Adva-27a was found to be effective at killing Pancreatic Cancer Cells in vitro. Based on initial data, the company is now advancing research using Adva-27a for pancreatic cancer treatment.
The initial study, as reported in June 2013, was carried out in the very aggressive Pancreatic Cancer cell line, Panc-1. Adva-27a was able to kill these cells with an IC50 of less than 4 micromolar, a pharmacologically very favorable drug concentration.
Adva-27a is Sunshine Biopharma's lead anticancer compound, a small molecule that has recently been shown to be effective at killing multidrug resistant breast cancer cells, small-cell lung cancer cells, uterine sarcoma cells and pancreatic cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Adva-27a is currently in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under US patent number 8,236,935.
According to Global Industry Analysts, Inc. in their recent report, "Eli Lilly's (NYSE:LLY) Gemzar (Gemcitabine) is the current gold standard of care for locally advanced and metastatic disease, with a dominance that is undisputed despite a median survival of less than 6 months and rate of one-year survival of around 18%, as stated by the new market research report on Pancreatic cancer drugs. Though the odds of survival are somewhat better in other forms of cancer, the rate of five-year survival for the most common form of pancreatic cancer, Adenocarcinoma of the pancreas is less than 5%, with majority of patients surviving just a few months. " - Big ideas for Global Investors is a global news source and resource base for investors following tech stocks, biometric stocks, water stocks, biotech stocks, energy stocks, mining stocks, renewable energy stocks, nanotech and Latin American stocks.
Follow on Twitter  
Follow on Facebook  
Follow News on
Sign up for free news alerts and get free research tools:
Join us and become an Member and access our online stock directories listing thousands of publicly traded stocks in leading sectors
Disclaimer/ Disclosure: The newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investor ideas is protected by copyright laws other than syndication rights. Investor ideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: Disclosure investor ideas has been compensated with 144 shares for news and content publication ( 100,000 per three month period)
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: Global investors must adhere to regulations of each country.
800-665-0411 -   Source –

No comments:

Post a Comment